Gonadotropin-releasing hormone antagonist (linzagolix): a new therapy for uterine adenomyosis

Donnez O, Olivier Donnez, Donnez J, Jacques Donnez
Fertility and sterility · 2020 · vol. 114(3) , pp. 640–645 · doi:10.1016/j.fertnstert.2020.04.017 · PMID:32507315 · W3033691887
article OA: closed CC0 ⤵ 37 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-07 ⓘ

Linzagolix, a gonadotropin-releasing hormone antagonist, has been investigated as a new therapeutic option for uterine adenomyosis.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

ObjectiveTo compare the efficacy of a selective progesterone receptor modulator, ulipristal acetate, and a gonadotropin-releasing hormone antagonist, linzagolix, in a case of severe uterine adenomyosis.DesignCase report.SettingPrivate clinic and infertility research unit.PatientOne patient born in 1981 who presented because of heavy menstrual bleeding, pelvic pain, and dysmenorrhea due to diffuse and disseminated uterine adenomyosis confirmed by magnetic resonance imaging (MRI).InterventionThe patient received a first treatment of 5 mg UPA daily for one course of 3 months. This therapy was discontinued because MRI revealed a worsened aspect. One year later, a once-daily dose of 200 mg linzagolix administered orally was initiated for 3 months, followed by another 3-month course of 100 mg once daily.Main outcome measuresClinical symptoms and MRI aspect.ResultsDuring treatment with UPA, the symptoms (pelvic pain, dysmenorrhea, bulk symptoms) worsened and MRI revealed aggravation of the adenomyotic lesions. During the 12-week course of once-daily 200 mg linzagolix, the patient remained in amenorrhea and noted a very significant improvement in symptoms. On MRI, the uterine volume had fallen from 875 cm3 to 290 cm3, and the adenomyotic lesions had significantly regressed. During the 100-mg linzagolix course (weeks 13-24), the patient reported continued alleviation of her symptoms.ConclusionTo our knowledge, this is the first reported use of linzagolix, a new oral gonadotropin-releasing hormone antagonist that significantly reduced lesion size and improved quality of life in a patient with severe adenomyosis, who was previously nonresponsive to treatment with a selective progesterone receptor modulator, ulipristal acetate.

My notes (saved in your browser only)

Condition tags

adenomyosis

MeSH descriptors

Adenomyosis Gonadotropin-Releasing Hormone Hormone Antagonists Norpregnadienes Uterus Adenomyosis Adenomyosis Adenomyosis Adult Disease Progression Drug Substitution Female Gonadotropin-Releasing Hormone Gonadotropin-Releasing Hormone Hormone Antagonists Humans Magnetic Resonance Imaging Norpregnadienes Remission Induction Severity of Illness Index

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (45)

Cited by (39)

Source provenance

europepmc
last seen: 2026-08-06T06:07:45.168820+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:21:59.141895+00:00
License: CC0 · commercial use OK